These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 25741135)
1. Anal cancer treatment: current status and future perspectives. Ghosn M; Kourie HR; Abdayem P; Antoun J; Nasr D World J Gastroenterol; 2015 Feb; 21(8):2294-302. PubMed ID: 25741135 [TBL] [Abstract][Full Text] [Related]
2. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724 [TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. Mai S; Welzel G; Ottstadt M; Lohr F; Severa S; Prigge ES; Wentzensen N; Trunk MJ; Wenz F; von Knebel-Doeberitz M; Reuschenbach M Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):819-27. PubMed ID: 26530750 [TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133 [TBL] [Abstract][Full Text] [Related]
6. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Bentzen AG; Guren MG; Wanderås EH; Frykholm G; Tveit KM; Wilsgaard T; Dahl O; Balteskard L Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e173-80. PubMed ID: 22436791 [TBL] [Abstract][Full Text] [Related]
7. Advances in the Management of Anal Cancer. Julie DR; Goodman KA Curr Oncol Rep; 2016 Mar; 18(3):20. PubMed ID: 26905274 [TBL] [Abstract][Full Text] [Related]
8. Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Abbas A; Yang G; Fakih M Oncology (Williston Park); 2010 Apr; 24(5):417-24. PubMed ID: 20480740 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Hauerstock D; Ennis RD; Grossbard M; Evans A Clin Colorectal Cancer; 2010 Oct; 9(4):238-42. PubMed ID: 20920996 [TBL] [Abstract][Full Text] [Related]
10. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775 [TBL] [Abstract][Full Text] [Related]
11. Review of anal cancer patients at the Ottawa hospital. Abunassar M; Reinders J; Jonker DJ; Asmis T Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438 [TBL] [Abstract][Full Text] [Related]
12. [Management of anal canal carcinoma]. Thang NN; Cochet S; George AC; Betz M; Roth A Rev Med Suisse; 2011 May; 7(296):1144-8. PubMed ID: 21721205 [TBL] [Abstract][Full Text] [Related]
13. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Glynne-Jones R; Sebag-Montefiore D; Meadows HM; Cunningham D; Begum R; Adab F; Benstead K; Harte RJ; Stewart J; Beare S; Hackshaw A; Kadalayil L; Lancet Oncol; 2017 Mar; 18(3):347-356. PubMed ID: 28209296 [TBL] [Abstract][Full Text] [Related]
14. Evolution and Management of Treatment-Related Toxicity in Anal Cancer. Ludmir EB; Kachnic LA; Czito BG Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040 [TBL] [Abstract][Full Text] [Related]
16. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Meulendijks D; Dewit L; Tomasoa NB; van Tinteren H; Beijnen JH; Schellens JH; Cats A Br J Cancer; 2014 Oct; 111(9):1726-33. PubMed ID: 25167226 [TBL] [Abstract][Full Text] [Related]
17. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859 [TBL] [Abstract][Full Text] [Related]
18. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. Khawandanah M; Baxley A; Pant S J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443 [TBL] [Abstract][Full Text] [Related]
20. [Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma. Long-term results of the phase III RTOG 98-11 trial]. Nieder C Strahlenther Onkol; 2013 Jun; 189(6):512-3. PubMed ID: 23609134 [No Abstract] [Full Text] [Related] [Next] [New Search]